JP2017525737A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525737A5
JP2017525737A5 JP2017512046A JP2017512046A JP2017525737A5 JP 2017525737 A5 JP2017525737 A5 JP 2017525737A5 JP 2017512046 A JP2017512046 A JP 2017512046A JP 2017512046 A JP2017512046 A JP 2017512046A JP 2017525737 A5 JP2017525737 A5 JP 2017525737A5
Authority
JP
Japan
Prior art keywords
group
alkyl
substituted
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525737A (ja
JP6506390B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/088799 external-priority patent/WO2016034108A1/zh
Publication of JP2017525737A publication Critical patent/JP2017525737A/ja
Publication of JP2017525737A5 publication Critical patent/JP2017525737A5/ja
Application granted granted Critical
Publication of JP6506390B2 publication Critical patent/JP6506390B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512046A 2014-09-02 2015-09-01 キノリノン系化合物及びその薬物への使用 Active JP6506390B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410442574.4 2014-09-02
CN201410442574 2014-09-02
PCT/CN2015/088799 WO2016034108A1 (zh) 2014-09-02 2015-09-01 喹啉酮类化合物及其应用

Publications (3)

Publication Number Publication Date
JP2017525737A JP2017525737A (ja) 2017-09-07
JP2017525737A5 true JP2017525737A5 (cg-RX-API-DMAC7.html) 2018-06-14
JP6506390B2 JP6506390B2 (ja) 2019-04-24

Family

ID=55417512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512046A Active JP6506390B2 (ja) 2014-09-02 2015-09-01 キノリノン系化合物及びその薬物への使用

Country Status (8)

Country Link
US (1) US10065928B2 (cg-RX-API-DMAC7.html)
EP (1) EP3190104B1 (cg-RX-API-DMAC7.html)
JP (1) JP6506390B2 (cg-RX-API-DMAC7.html)
CN (1) CN105384687B (cg-RX-API-DMAC7.html)
AU (1) AU2015311333B2 (cg-RX-API-DMAC7.html)
CA (1) CA2959688C (cg-RX-API-DMAC7.html)
ES (1) ES2898476T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016034108A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN108069952B (zh) * 2016-11-08 2022-09-27 广东东阳光药业有限公司 喹啉酮类化合物及其在药物中应用
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
CN108285460A (zh) * 2017-01-09 2018-07-17 南京圣和药业股份有限公司 一种egfr激酶抑制剂的药用盐及其制备方法与用途
JP6999469B2 (ja) * 2018-03-28 2022-01-18 東京応化工業株式会社 水素バリア剤、水素バリア膜形成用組成物、水素バリア膜、水素バリア膜の製造方法、及び電子素子
CN111269177B (zh) * 2019-11-28 2023-05-09 广东东阳光药业有限公司 喹啉酮类化合物的晶型
CN111269178A (zh) * 2019-11-28 2020-06-12 南北兄弟药业投资有限公司 喹啉酮类化合物的晶型
CN111269176A (zh) * 2019-11-28 2020-06-12 南北兄弟药业投资有限公司 喹啉酮类化合物的晶型
WO2021104353A1 (zh) 2019-11-28 2021-06-03 广东东阳光药业有限公司 喹啉酮类化合物的晶型及其用途
CN115010662B (zh) * 2021-03-05 2023-12-08 广东东阳光药业股份有限公司 喹啉酮类化合物的晶型及其用途
CN115010663A (zh) * 2021-03-05 2022-09-06 广东东阳光药业有限公司 喹啉酮类化合物的晶型及其用途
CN115010664A (zh) * 2021-03-05 2022-09-06 广东东阳光药业有限公司 喹啉酮类化合物的晶型及其用途
CN114989085B (zh) * 2022-05-23 2023-11-24 安徽医科大学 一种芳基内酰胺环类化合物、药物组合物及其应用
CN117159549B (zh) * 2023-10-11 2025-02-14 中国药科大学 一种酯类化合物的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543448A (en) * 2003-06-06 2009-02-28 Fibrogen Inc Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin
JPWO2006088246A1 (ja) * 2005-02-18 2008-07-10 武田薬品工業株式会社 Gpr34受容体機能調節剤
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
ES2446416T3 (es) * 2005-12-09 2014-03-07 Amgen, Inc. Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos
AU2007211077B2 (en) 2006-01-27 2012-09-20 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (HIF)
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
MX2008012734A (es) 2006-04-04 2009-01-29 Fibrogen Inc Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif).
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
AU2007265460B2 (en) 2006-06-26 2011-03-03 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
WO2008076427A2 (en) 2006-12-18 2008-06-26 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
AU2007334321B2 (en) 2006-12-18 2012-03-08 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CA2683758A1 (en) * 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
JP2010524942A (ja) 2007-04-18 2010-07-22 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
CA2685216C (en) 2007-05-04 2014-07-08 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
KR20100045480A (ko) 2007-08-10 2010-05-03 크리스탈지노믹스(주) 피리딘 유도체 및 이들의 사용방법
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039322A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009070644A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2011508725A (ja) 2007-11-30 2011-03-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
JP2011507894A (ja) 2007-12-19 2011-03-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
CN101951776A (zh) 2008-02-25 2011-01-19 默沙东公司 四氢-1h-吡咯稠合吡啶酮
CN101951777A (zh) 2008-02-25 2011-01-19 默沙东公司 四氢呋喃并吡啶酮
EP2257169B1 (en) 2008-02-25 2013-06-05 Merck Sharp & Dohme Corp. Tetrahydrothieno pyridines
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
WO2009134850A1 (en) 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009134847A1 (en) 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2011525924A (ja) 2008-06-25 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
EP2334682B1 (en) 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
JP2012500802A (ja) 2008-08-21 2012-01-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
EP2326179A4 (en) 2008-08-25 2011-08-17 Smithkline Beecham Corp PROLYLHYDROXYLASEHEMMER
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
EP2396316B1 (en) 2009-02-10 2015-07-01 Janssen Pharmaceutica, N.V. Quinazolinones as prolyl hydroxylase inhibitors
IN2012DN00549A (cg-RX-API-DMAC7.html) 2009-07-15 2015-06-12 Zhejiang Beta Pharma Inc
AR077417A1 (es) 2009-07-17 2011-08-24 Japan Tobacco Inc Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa o agente inductor de la produccion de eritropoyetina
WO2011048611A1 (en) 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
TWI500623B (zh) 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
WO2011056725A1 (en) 2009-11-05 2011-05-12 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
US8541430B2 (en) 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones
US8796263B2 (en) 2010-08-13 2014-08-05 Janssen Pharmaceutica Nv 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
US8865748B2 (en) 2011-06-06 2014-10-21 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (cg-RX-API-DMAC7.html) 2011-06-06 2018-03-17
CA2843240A1 (en) 2011-07-29 2013-02-07 Beijing Betta Pharmaceuticals Co., Ltd Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof
NZ700760A (en) 2012-03-09 2016-08-26 Fibrogen Inc 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
EP2872487B1 (en) 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
IN2015DN01035A (cg-RX-API-DMAC7.html) 2012-07-30 2015-06-26 Taisho Pharmaceutical Co Ltd
US20150239889A1 (en) 2012-08-23 2015-08-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound
KR101733901B1 (ko) * 2012-12-24 2017-05-08 카딜라 핼쓰캐어 리미티드 신규한 퀴놀론 유도체
MX360048B (es) 2013-01-24 2018-10-19 Fibrogen Inc Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.

Similar Documents

Publication Publication Date Title
JP2017525737A5 (cg-RX-API-DMAC7.html)
JP2014511891A5 (cg-RX-API-DMAC7.html)
JP2019524883A5 (cg-RX-API-DMAC7.html)
JP2010532387A5 (cg-RX-API-DMAC7.html)
JP2017527561A5 (cg-RX-API-DMAC7.html)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
JP2017531619A5 (cg-RX-API-DMAC7.html)
JP2015522650A5 (cg-RX-API-DMAC7.html)
JP2015537020A5 (cg-RX-API-DMAC7.html)
JP2016540742A5 (cg-RX-API-DMAC7.html)
JP2016505512A5 (cg-RX-API-DMAC7.html)
JP2014507455A5 (cg-RX-API-DMAC7.html)
JP2018514544A5 (cg-RX-API-DMAC7.html)
JP2020529994A5 (cg-RX-API-DMAC7.html)
JP2015524472A5 (cg-RX-API-DMAC7.html)
JP2013542261A5 (cg-RX-API-DMAC7.html)
JP2016531126A5 (cg-RX-API-DMAC7.html)
JP2019510034A5 (cg-RX-API-DMAC7.html)
JP2019531279A5 (cg-RX-API-DMAC7.html)
JP2016507581A5 (cg-RX-API-DMAC7.html)
RU2012158142A (ru) Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
RU2015146957A (ru) Производные доластатина 10 и ауристатинов
JP2015521195A5 (cg-RX-API-DMAC7.html)
JP2017516796A5 (cg-RX-API-DMAC7.html)
JP2018528229A5 (cg-RX-API-DMAC7.html)